When was Inbrija approved by the FDA?

Written by Teresa Carvalho, MS | June 14, 2023

When was Inbrija approved by the FDA?

Category: Inbrija

The U.S. Food and Drug Administration (FDA) approved Inbrija in December 2018 as an add-on treatment for off periods in Parkinson’s disease patients on levodopa and carbidopa. That decision made Inbrija the first inhaled levodopa therapy in the U.S. for Parkinson’s off episodes.

About the Author

Teresa Carvalho, MS Teresa holds her Master of Science in cell and molecular biology from Coimbra University, Portugal. She was a researcher and science communicator for several years at the Institute for Research and Innovation in Health in Oporto, Portugal. From 2013, she has held a fellowship working with Pulmonary Hypertension Europe as a patient advocate, social media/website manager, public relations officer, and translator. Her work has been focused on providing patients access to treatments, raising awareness for pulmonary hypertension, and promoting patient empowerment.